Nuvalent Inc
NUVL
查看详细走势图
103.800USD
+2.390+2.36%
收盘 12/19, 16:00（美东）报价延迟15分钟
7.50B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.36%
5天
-0.95%
1月
-3.90%
6月
+38.40%
今年开始到现在
+32.60%
1年
+23.25%
查看详细走势图
TradingKey Nuvalent Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nuvalent Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
18
位分析师
买入
评级
140.000
目标均价
+29.79%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Nuvalent Inc亮点
亮点风险
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值合理
公司最新PE估值-19.88，处于3年历史合理位
机构减仓
最新机构持股72.76M股，环比减少4.99%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值175.00
Nuvalent Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nuvalent Inc简介
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
公司代码NUVL
公司Nuvalent Inc
CEOPorter (James R)
网址https://www.nuvalent.com/
常见问题
Nuvalent Inc(NUVL)的当前股价是多少？
Nuvalent Inc(NUVL)的当前股价是 103.800。
Nuvalent Inc的股票代码是什么？
Nuvalent Inc的股票代码是NUVL。
Nuvalent Inc股票的52周最高点是多少？
Nuvalent Inc股票的52周最高点是112.880。
Nuvalent Inc股票的52周最低点是多少？
Nuvalent Inc股票的52周最低点是55.535。
Nuvalent Inc的市值是多少？
Nuvalent Inc的市值是7.50B。
Nuvalent Inc的净利润是多少？
Nuvalent Inc的净利润为-260.76M。
现在Nuvalent Inc(NUVL)的股票是买入、持有还是卖出？
根据分析师评级，Nuvalent Inc(NUVL)的总体评级为买入，目标价格为140.000。
Nuvalent Inc(NUVL)股票的每股收益（EPS TTM）是多少
Nuvalent Inc(NUVL)股票的每股收益（EPS TTM）是-5.324。
相关品种
